Understand Business Like AI

Training Example: VABYSMO (Genentech) – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

VABYSMO (Genentech)

(https://vabysmo.com) 📸 Data Snapshot: May 26, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE VABYSMO® (faricimab-svoa) | Wet AMD, DME and RVO Treatment (https://vabysmo.com)
Title

VABYSMO® (faricimab-svoa) | Wet AMD, DME and RVO Treatment

Meta

VABYSMO® (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with wet AMD, DME, and RVO.

H2 Wet AMD
H2 DME
H2 RVO
H2 IMPORTANT SAFETY INFORMATION
H3 Select your condition below:
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H4 #1 PRESCRIBED FDA-APPROVED TREATMENT FOR WET AMD*
H4 VABYSMO improves vision quickly.† It’s different. VABYSMO is the only FDA-approved treatment thought to block 2 causes of vision loss.‡
H4 VABYSMO improves vision quickly.† It’s different. VABYSMO is the only FDA-approved treatment thought to block 2 causes of vision loss.‡
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
NAV_HEADER_REPEATED VABYSMO® (faricimab-svoa) Important Safety Information (https://vabysmo.com/important-safety-information.html)
Title

VABYSMO® (faricimab-svoa) Important Safety Information

Meta

Find Important Safety Information about VABYSMO™ (faricimab-svoa). See full safety for more information.

H1 Important Safety Information
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
NAV_HEADER_REPEATED Spanish homepage (https://vabysmo.com/es/index.html)
Title

Spanish homepage

Meta

VABYSMO® (faricimab-svoa) Spanish Efficacy, Safety, Dosing & Prescribing Info

H2 INFORMACIÓN DE SEGURIDAD IMPORTANTE
H3 VABYSMO mejora la visión rápidamente*
H3 Nina
H3 Nina
H3 VABYSMO ofrece la posibilidad de hasta 4 meses entre tratamientos#
H3 Armye
H3 Armye
H3 Access Solutions de oftalmología de Genentech
H3 TE ENTENDEMOS. TE AYUDAMOS. TE APOYAMOS.
H3 Queremos apoyar tu experiencia
H3 TE ENTENDEMOS. TE AYUDAMOS. TE APOYAMOS.
H3 Queremos apoyar tu experiencia
H4 APROBADO PARA EL TRATAMIENTO DEL EDEMA MACULAR DIABÉTICO (DME)
H4 Opciones de asequibilidad:
H4 Opciones de asequibilidad:
H5 “El medicamento VABYSMO es una bendición para mí. La mejora de mi visión* me ha devuelto la Nina que era antes, probablemente más fuerte que nunca. Es como si fuera una segunda oportunidad para todo”.
H5 Paciente de VABYSMO
H5 “El medicamento VABYSMO es una bendición para mí. La mejora de mi visión* me ha devuelto la Nina que era antes, probablemente más fuerte que nunca. Es como si fuera una segunda oportunidad para todo”.
H5 Paciente de VABYSMO
H5 La frecuencia con la que recibirás VABYSMO dependerá de cómo respondan tus ojos.
H5 Tu especialista en retina elegirá uno de los siguientes programas:
H5 1. Después de 4 inyecciones mensuales iniciales, puedes pasar de 1 a 4 meses entre tratamientos.
H5 2. Después de 6 inyecciones mensuales iniciales, puedes pasar 2 meses entre tratamientos.
H5 Aunque la mayoría de las personas de los ensayos clínicos pasaron de 3 a 4 meses entre inyecciones, puede no ser una experiencia común a todas las personas. Tu especialista en retina puede evaluar tu enfermedad de forma diferente a los métodos utilizados en nuestros ensayos.
H5 “Después de la primera inyección, noté una diferencia en mi visión*”.
H5 Paciente de VABYSMO
H5 “Después de la primera inyección, noté una diferencia en mi visión*”.
H5 Paciente de VABYSMO
H5 Programa de Copago de oftalmología de Genentech:*
H5 Fundación de Pacientes de Genentech:†
H5 Fundaciones independientes de asistencia con los copagos:‡
H5 Programa de Copago de oftalmología de Genentech:*
H5 Fundación de Pacientes de Genentech:†
H5 Fundaciones independientes de asistencia con los copagos:‡
H6 Nos comprometemos a ayudarte a entender tu cobertura de seguro y las opciones de asistencia.
HEADING_REPEATED_BODY Treatment for Wet AMD | VABYSMO® (faricimab-svoa) (https://vabysmo.com/wamd.html)
Title

Treatment for Wet AMD | VABYSMO® (faricimab-svoa)

Meta

VABYSMO® (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with wet AMD.

H2 What is VABYSMO?
H2 Treatment with VABYSMO
H2 Financial support
H2 IMPORTANT SAFETY INFORMATION
H3 Why VABYSMO might be right for you
H3 Discover how VABYSMO could Open Up Your World
H3 Capturing All The Action | Open Up Your World
H3 Adventure Awaits | Open Up Your World
H3 David
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H4 #1 PRESCRIBED FDA-APPROVED TREATMENT FOR WET AMD*
H4 "My vision progressively got better, and I could see better.Ӧ
H5 VABYSMO patient
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://vabysmo.com) VABYSMO® (faricimab-svoa) | Wet AMD, DME and RVO Treatment 
[H4] #1 PRESCRIBED FDA-APPROVED TREATMENT FOR WET AMD*
*Verana Health® patient share analysis (Apr-Jun 2025); products approved under separate applications considered individually (data on file).

[H3] Select your condition below:

[H2] Wet AMD
Wet age-related macular degeneration

Explore

[H2] DME
Diabetic macular edema

Explore

[H2] RVO
Macular edema following retinal vein occlusion

Explore

[H4] VABYSMO improves vision quickly.†
It’s different. VABYSMO is the only FDA-approved treatment thought to block 2 causes of vision loss.‡
[H4] VABYSMO improves vision quickly.†
It’s different. VABYSMO is the only FDA-approved treatment thought to block 2 causes of vision loss.‡

†Wet AMD: On average, people gained 5 letters at 1 month after their first treatment and gained and maintained 6 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg. DME: On average, people gained 6 letters at 1 month after their first treatment and gained and maintained 11 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg. RVO: On average, people with CRVO gained 13 letters at 1 month after their first treatment while people with BRVO gained 11 letters at 1 month after their first treatment on an eye chart with VABYSMO, similar to aflibercept 2 mg. On average, people with CRVO and BRVO gained and maintained 17 letters over 6 months on an eye chart with VABYSMO, similar to aflibercept 2 mg.
‡VABYSMO is thought to block the VEGF and Ang-2 proteins. The benefit of blocking Ang-2 has yet to be established.
Ang-2=angiopoietin-2; BRVO=branch retinal vein occlusion; CRVO=central retinal vein occlusion; VEGF=vascular endothelial growth factor.

VABYSMO (faricimab-svoa) is a VEGF and Ang-2 inhibitor used to treat adults with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).
VABYSMO is thought to block 2 causes of vision loss (VEGF and Ang-2)‡, which helps to reduce abnormal blood vessel swelling, leakage, and growth. The benefit of blocking Ang-2 has yet to be established. It also improves vision quickly.† On average, people gained 5 letters at 1 month after their first treatment and gained and maintained 6 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg.
VABYSMO given by injection into the eye. For wet AMD and DME, initial dosing will be every 4 weeks, then dosing is determined by your doctor based on how you respond. You may be able to go up to 4 months between treatments§. For RVO, dosing is given every 4 weeks for 6 months.
The possible serious side effects of VABYSMO were inflammation and detached retina (separation of the retina from the back of the eye); a temporary increase in eye pressure; although not common, there is a risk of a stroke or heart attack; severe inflammation of vessels in the retina.

[H2]
IMPORTANT SAFETY INFORMATION

Back to Top

What is VABYSMO?
VABYSMO (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with neovascular (wet) age‑related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).
Do not receive VABYSMO if you:
Have an infection in or around your eye.
Have active swelling around your eye that may include pain and redness.
Are allergic to VABYSMO or any of the ingredients in VABYSMO.

What is the most important information I should know about VABYSMO?
Injections like the one for VABYSMO can cause an eye infection (endophthalmitis), separation of layers of the retina (retinal detachment), or inflammation in the eye that can lead to vision loss. Call your healthcare provider right away if your eye becomes red, sensitive to light, or you have a change or loss of vision.
VABYSMO may cause a temporary increase in pressure in the eye (intraocular pressure), which occurs within 60 minutes after receiving the eye injection.
Although not common, VABYSMO patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes (thromboembolic events). In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with VABYSMO reported such an event. In clinical studies for DME from baseline to week 100, 64 out of 1,262 patients treated with VABYSMO reported such an event. In clinical studies for RVO during 6 months, 7 out of 641 patients treated with VABYSMO reported such an event.
Severe inflammation of vessels in the retina has happened for patients treated with VABYSMO. Call your healthcare provider immediately if you experience a change in vision.
Before receiving VABYSMO, tell your healthcare provider about all of your medical conditions, including if you:
Are pregnant or plan to become pregnant. Based on how VABYSMO interacts with your body, there may be a potential risk to your unborn baby. You should use birth control before your first injection, during your treatment with VABYSMO, and for 3 months after your last dose of VABYSMO.
Are breastfeeding or plan to breastfeed. It is not known if VABYSMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive VABYSMO.
Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about all the medicines you take.
What should I avoid while receiving VABYSMO?
Your vision may be impaired after receiving an eye injection or after an eye exam. Do not drive or use machinery until your vision has recovered sufficiently.
What are the most common side effects with VABYSMO?
The most common side effects with VABYSMO were cataract and blood on the white of the eye (conjunctival hemorrhage).
These are not all the possible side effects of VABYSMO.
Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.
Please see the VABYSMO full Prescribing Information for additional Important Safety Information.
6380 chars
SUB-PAGE (https://vabysmo.com/important-safety-information.html) VABYSMO® (faricimab-svoa) Important Safety Information 
Important Safety Information

[H1] Important Safety Information

What is VABYSMO?

VABYSMO (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).

Do not receive VABYSMO if you:

Have an infection in or around your eye.
Have active swelling around your eye that may include pain and redness.
Are allergic to VABYSMO or any of the ingredients in VABYSMO.

What is the most important information I should know about VABYSMO?

Injections like the one for VABYSMO can cause an eye infection (endophthalmitis) or separation of layers of the retina (retinal detachment). Call your healthcare provider right away if you have increasing eye pain, vision loss, sensitivity to light, or redness in the white of the eye.
VABYSMO may cause a temporary increase in pressure in the eye (intraocular pressure), which occurs within 60 minutes after receiving the eye injection.
Although not common, VABYSMO patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes (thromboembolic events). In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with VABYSMO reported such an event. In clinical studies for DME from baseline to week 100, 64 out of 1,262 patients treated with VABYSMO reported such an event. In clinical studies for RVO during 6 months, 7 out of 641 patients treated with VABYSMO reported such an event.
Severe inflammation of vessels in the retina has happened for patients treated with VABYSMO. Call your healthcare provider immediately if you experience a change in vision.

Before receiving VABYSMO, tell your healthcare provider about all of your medical conditions, including if you:

Are pregnant or plan to become pregnant. Based on how VABYSMO interacts with your body, there may be a potential risk to your unborn baby. You should use birth control before your first injection, during your treatment with VABYSMO, and for 3 months after your last dose of VABYSMO.
Are breastfeeding or plan to breastfeed. It is not known if VABYSMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive VABYSMO.
Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about all the medicines you take.

What should I avoid while receiving VABYSMO?

Your vision may be impaired after receiving an eye injection or after an eye exam. Do not drive or use machinery until your vision has recovered sufficiently.

What are the most common side effects with VABYSMO?

The most common side effects with VABYSMO were cataract and blood on the white of the eye (conjunctival hemorrhage).
These are not all the possible side effects of VABYSMO.

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.
Please see the VABYSMO full Prescribing Information for additional Important Safety Information.
3389 chars
SUB-PAGE (https://vabysmo.com/es/index.html) Spanish homepage 
[IMG: OPEN UP YOUR WORLD WITH VABYSMO®]

[H4] APROBADO PARA EL TRATAMIENTO DEL EDEMA MACULAR DIABÉTICO (DME)

Ir a la sección

PLAN PARA TU VISIÓN

TIEMPO ENTRE TRATAMIENTOS

ASISTENCIA FINANCIERA

PLAN PARA TU VISIÓN

[H3] VABYSMO mejora la visión rápidamente*

VABYSMO actúa desde la primera inyección mejorando la visión* para ayudarte a volver a las cosas que disfrutas.

[IMG: Infographic: Treatment timeline]

*En promedio, las personas recuperaron 6 letras 1 mes después de su primer tratamiento y recuperaron y mantuvieron 11 letras en una tabla optométrica durante 1 año con VABYSMO, similar a lo logrado con 2 mg de aflibercept.
†En 2 ensayos clínicos, se demostró que VABYSMO elimina el exceso de líquido dañino en el ojo, similar a lo logrado con 2 mg de aflibercept.
‡VABYSMO se evaluó en 2 estudios clínicos frente a 2 mg de aflibercept en 1,891 personas con DME. En ambos estudios, se demostró la no inferioridad frente a 2 mg de aflibercept en el criterio principal de valoración, definido como el cambio medio respecto del momento inicial en una mejor agudeza visual corregida (MAVC) en el año 1.
§"Mantener" se define como no perder 15 letras o más.

[IMG: Vabysmo patient - Nina]

[IMG: Icon - Quote mark]

[H5] “El medicamento VABYSMO es una bendición para mí. La mejora de mi visión* me ha devuelto la Nina que era antes, probablemente más fuerte que nunca. Es como si fuera una segunda oportunidad para todo”.
[H3] Nina
[H5] Paciente de VABYSMO

[IMG: Vabysmo patient - Nina]

[IMG: Icon - Quote mark]

[H5] “El medicamento VABYSMO es una bendición para mí. La mejora de mi visión* me ha devuelto la Nina que era antes, probablemente más fuerte que nunca. Es como si fuera una segunda oportunidad para todo”.
[H3] Nina
[H5] Paciente de VABYSMO

Las experiencias de los pacientes pueden variar. Paciente compensado por Genentech.

TIEMPO ENTRE TRATAMIENTOS

[H3] VABYSMO ofrece la posibilidad de hasta 4 meses entre tratamientos#

[H5] La frecuencia con la que recibirás VABYSMO dependerá de cómo respondan tus ojos.
[H5] Tu especialista en retina elegirá uno de los siguientes programas:
[H5] 1. Después de 4 inyecciones mensuales iniciales, puedes pasar de 1 a 4 meses entre tratamientos.

[IMG: Chart: Treatment interval after 4 treatments]

[H5] 2. Después de 6 inyecciones mensuales iniciales, puedes pasar 2 meses entre tratamientos.

[IMG: Chart: Treatment interval after 6 treatments]

[H5] Aunque la mayoría de las personas de los ensayos clínicos pasaron de 3 a 4 meses entre inyecciones, puede no ser una experiencia común a todas las personas. Tu especialista en retina puede evaluar tu enfermedad de forma diferente a los métodos utilizados en nuestros ensayos.

#Después de 4 o 6 inyecciones oculares mensuales iniciales, tu médico elegirá un programa de 1 a 4 meses, según la respuesta del paciente. La dosificación puede variar.

[H5] “Después de la primera inyección, noté una diferencia en mi visión*”.
[H3] Armye
[H5] Paciente de VABYSMO

[IMG: Vabysmo patient - Armye]

[IMG: Icon - Quote mark]

[IMG: Vabysmo patient - Armye]

[IMG: Icon - Quote mark]

[H5] “Después de la primera inyección, noté una diferencia en mi visión*”.
[H3] Armye
[H5] Paciente de VABYSMO

Las experiencias de los pacientes pueden variar. Paciente compensado por Genentech.

ASISTENCIA FINANCIERA

[H3] Access Solutions de oftalmología de Genentech

[H6] Nos comprometemos a ayudarte a entender tu cobertura de seguro y las opciones de asistencia.
Trabajamos con tu especialista en retina, tu seguro de salud y tu farmacia especializada para ayudarte a tener acceso al tratamiento de oftalmología que te recetó tu especialista en retina.

[H4] Opciones de asequibilidad:

[IMG: Icon - Zero Dollars]

[H5] Programa de Copago de oftalmología de Genentech:*
Para las personas que tienen seguro de salud y no pueden pagar su medicamento de Genentech. Los pacientes elegibles con seguro comercial podrían pagar tan solo $0 por el fármaco y copago de administración. Asistencia para copagos de hasta $15,000 por año calendario.

[IMG: Icon - Checklist]

[H5] Fundación de Pacientes de Genentech:†
Si no tienes cobertura de seguro o tienes problemas financieros y cumples con los criterios de elegibilidad, es posible que puedas recibir el tratamiento sin costo.

[IMG: Icon - User]

[H5] Fundaciones independientes de asistencia con los copagos:‡
Podemos dirigirte a una organización benéfica que podría ayudarte a pagar tu tratamiento.

[H4] Opciones de asequibilidad:

[IMG: Icon - Zero Dollars]

[H5] Programa de Copago de oftalmología de Genentech:*
Para las personas que tienen seguro de salud y no pueden pagar su medicamento de Genentech. Los pacientes elegibles con seguro comercial podrían pagar tan solo $0 por el fármaco y copago de administración. Asistencia para copagos de hasta $15,000 por año calendario.

[IMG: Icon - Checklist]

[H5] Fundación de Pacientes de Genentech:†
Si no tienes cobertura de seguro o tienes problemas financieros y cumples con los criterios de elegibilidad, es posible que puedas recibir el tratamiento sin costo.

[IMG: Icon - User]

[H5] Fundaciones independientes de asistencia con los copagos:‡
Podemos dirigirte a una organización benéfica que podría ayudarte a pagar tu tratamiento.

[H3] TE ENTENDEMOS.
TE AYUDAMOS.
TE APOYAMOS.

Además de nuestra línea de apoyo (833) EYE-GENE / (833) 393-4363, ya disponible en español de lunes a viernes, de 9 a. m. a 8 p. m., hora del este, podrás contar con un equipo que habla tu mismo idioma. Cuando tu proveedor de atención médica te refiera a un especialista, asegúrate de mencionar que necesitas más información o asistencia en español, así nuestros representantes podrán comunicarse contigo y atenderte en español.
Llama al (833) 393-4363, disponible en español.
Visita el sitio web para obtener más información sobre las soluciones de acceso en español que te puede ofrecer Genentech.

Descubre más

[H3] Queremos apoyar tu experiencia

Explora nuestro folleto para obtener información útil sobre VABYSMO y saber qué esperar durante el tratamiento.

Descargar ahora

[H3] TE ENTENDEMOS.
TE AYUDAMOS.
TE APOYAMOS.

Además de nuestra línea de apoyo (833) EYE-GENE / (833) 393-4363, ya disponible en español de lunes a viernes, de 9 a. m. a 8 p. m., hora del este, podrás contar con un equipo que habla tu mismo idioma. Cuando tu proveedor de atención médica te refiera a un especialista, asegúrate de mencionar que necesitas más información o asistencia en español, así nuestros representantes podrán comunicarse contigo y atenderte en español.
Llama al (833) 393-4363, disponible en español.
Visita el sitio web para obtener más información sobre las soluciones de acceso en español que te puede ofrecer Genentech.

Descubre más

[H3] Queremos apoyar tu experiencia

Explora nuestro folleto para obtener información útil sobre VABYSMO y saber qué esperar durante el tratamiento.

Descargar ahora

*Los Programas de Copago por Producto y por Administración (“Programas”) son válidos SOLAMENTE para pacientes con seguro comercial (privado o no gubernamental) que tengan una receta válida para una indicación de un medicamento de Genentech aprobada por la Administración de Alimentos y Medicamentos (FDA, por sus siglas en inglés). Los Programas no están disponibles para pacientes cuyas recetas sean reembolsadas en virtud de programas de seguro federales, estatales o financiados por el gobierno (incluidos, entre otros, Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Programas del Departamento de Defensa [DoD, por sus siglas en inglés] o de Asuntos de los Veteranos [VA, por sus siglas en inglés]) o cuando lo prohíba la ley o el proveedor de seguro médico del paciente. Si en cualquier momento un paciente comienza a recibir cobertura de fármacos recetados en virtud de cualquiera de dichos programas de atención médica federales, estatales o financiados por el gobierno, el paciente ya no será elegible para los Programas.
En virtud de los Programas, podría exigirse al paciente que pague un copago por los costos de los medicamentos y un copago por los costos de administración. El monto final que un paciente adeude por el medicamento de Genentech o la administración del medicamento de Genentech puede ser tan bajo como $0 (consulte los detalles específicos del Programa disponibles en el sitio web del Programa). El costo total del gasto directo del bolsillo del paciente depende de su plan de seguro de salud. Los Programas solo ayudan con el costo del medicamento de Genentech y la administración del medicamento de Genentech. No ayuda con el costo de otras administraciones, medicamentos, procedimientos o visitas al consultorio. Después de alcanzar los montos máximos del beneficio de los Programas, el paciente será responsable de todos los gastos directos del bolsillo restantes. El monto de los beneficios de los Programas no puede exceder los gastos directos del bolsillo del paciente por el costo del medicamento de Genentech o los gastos de administración del medicamento de Genentech.
Todos los participantes son responsables de notificar la recepción de todos los beneficios de los Programas según lo requiera cualquier aseguradora o la ley. Los Programas solo son válidos en los Estados Unidos y sus territorios, y no son válidos donde estén prohibidos por la ley. El Programa de Copago de Fármacos deberá seguir las restricciones estatales relacionadas con la categoría AB de medicamentos equivalentes genéricos (p. ej., Massachusetts, California) donde corresponda. El Programa de Copago por Administración no es válido para pacientes que residen o reciben tratamiento en un estado restringido (p. ej., Massachusetts o Rhode Island). Ninguna parte intentará obtener un reembolso total ni parcial del beneficio que se recibe a través de los Programas. El valor de los Programas está destinado exclusivamente al beneficio del paciente. Los fondos disponibles a través de los Programas solo pueden usarse para reducir los costos de bolsillo del paciente inscrito en los Programas. Los Programas no están destinados al beneficio de terceros, incluidos, entre otros, pagadores externos, administradores de beneficios farmacéuticos o sus agentes. Si Genentech determina que un tercero ha implementado programas que ajustan las obligaciones de costos compartidos de los pacientes en función de la disponibilidad de apoyo en virtud de los Programas y/o no contabiliza la asistencia proporcionada en virtud de los Programas para las limitaciones de los deducibles o de los costos de bolsillo del paciente, Genentech puede imponer un límite de asignación en la asistencia de costos compartidos disponible en virtud de los Programas. El envío de información veraz y precisa es un requisito de elegibilidad y Genentech se reserva el derecho de descalificar a los pacientes que no cumplan con los Términos y Condiciones del Programa de Genentech. Genentech se reserva el derecho de rescindir, revocar o enmendar los Programas en cualquier momento, sin previo aviso.
Se aplican términos y condiciones adicionales. Visite el sitio web del Programa de Copago para obtener la lista completa de Términos y Condiciones.
†Si tiene seguro de salud, ya debe haber probado otros tipos de asistencia financiera, si están disponibles. También debe cumplir con los criterios de ingresos. Si no tiene seguro de salud o si su seguro no cubre el tratamiento oftalmológico de Genentech, debe cumplir con diferentes criterios de ingresos. Genentech se reserva el derecho de modificar o discontinuar el programa en cualquier momento y de verificar la exactitud de la información enviada.
‡Las fundaciones independientes de asistencia con los copagos tienen sus propias reglas de elegibilidad. Genentech no participa ni influye en las decisiones de las fundaciones independientes o en sus criterios de elegibilidad, y no sabemos si una fundación podrá brindarte ayuda. Solo le remitimos a una fundación que apoya el estado de su enfermedad. Genentech no respalda ni muestra preferencia por ninguna fundación en particular. Las fundaciones a las que le remitimos no son las únicas que podrían ayudarle.

[H2]
INFORMACIÓN DE SEGURIDAD IMPORTANTE

Regresar al inicio

¿Qué es VABYSMO?
VABYSMO (faricimab-svoa) es un medicamento de venta con receta que se administra mediante inyección ocular y se usa para tratar a los adultos con degeneración macular asociada a la edad (AMD, por sus siglas en inglés) neovascular (húmeda), edema macular diabético (DME, por sus siglas en inglés) y edema macular después de una oclusión venosa retiniana (RVO, por sus siglas en inglés).
No reciba VABYSMO si:
Tiene una infección ocular o alrededor del ojo.
Tiene una hinchazón activa alrededor del ojo que puede incluir dolor y enrojecimiento.
Es alérgico a VABYSMO o a cualquiera de los ingredientes de VABYSMO.

¿Cuál es la información más importante que debo saber sobre VABYSMO?
Inyecciones como la de VABYSMO pueden causar una infección ocular (endoftalmitis) o la separación de las capas de la retina (desprendimiento de retina), o inflamación del ojo que puede causar pérdida de la visión. Llame a su proveedor de atención médica de inmediato si tiene enrojecimiento en el ojo, sensibilidad a la luz o experimenta un cambio o pérdida de la visión.
VABYSMO puede causar un aumento temporal de la presión en el ojo (presión intraocular), que ocurre 60 minutos después de recibir la inyección ocular.
Aunque no son frecuentes, los pacientes que reciben VABYSMO han tenido problemas graves, a veces mortales, relacionados con coágulos de sangre, como ataques cardíacos o accidentes cerebrovasculares (eventos tromboembólicos). En estudios clínicos sobre la AMD húmeda durante el primer año, 7 de 664 pacientes tratados con VABYSMO informaron dicho evento. En estudios clínicos sobre el DME, desde el inicio hasta la semana 100, 64 de los 1,262 pacientes tratados con VABYSMO informaron dicho evento. En estudios clínicos sobre la RVO durante 6 meses, 7 de 641 pacientes tratados con VABYSMO informaron dicho evento.
Se ha producido una inflamación grave de los vasos sanguíneos de
15000 chars
SUB-PAGE (https://vabysmo.com/wamd.html) Treatment for Wet AMD | VABYSMO® (faricimab-svoa) 
[H4] #1 PRESCRIBED FDA-APPROVED TREATMENT FOR WET AMD*
*Verana Health® patient share analysis (Apr-Jun 2025); products approved under separate applications considered individually (data on file).

[H3] Why VABYSMO might be right for you

[IMG: Icon - eye]

Improves vision quickly†

[IMG: Icon - double-check]

It’s the only FDA-approved treatment thought to block 2 causes of wet AMD‡

[IMG: Icon - 4-treatment]

Delivers a chance for up to 4 months between treatments§

†On average, people gained 5 letters at 1 month after their first treatment and gained and maintained 6 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg.
‡VABYSMO is thought to block the VEGF and Ang-2 proteins. The benefit of blocking Ang-2 has yet to be established.
§After 4 initial monthly eye injections, your doctor will choose a schedule of 1 to 4 months based on patient response during your first year of treatment. Dosing may vary.
Ang-2=angiopoietin-2; VEGF=vascular endothelial growth factor.

[H3] Discover how VABYSMO could Open Up Your World

[H3]

[H3] Capturing All The Action | Open Up Your World
When he started to lose his vision due to wet AMD, he was worried about missing out on all the action. Then he heard about VABYSMO and now he can continue his passion for sports photography, capturing each moment at every turn.

Now Playing 1 of 2
Open Transcript

Male Narrator: How did I get here? Shooting all the action despite vision loss from wet AMD.
Super: Wet AMD (Age-related Macular Degeneration)
Male Narrator: It started when VABYSMO opened up my world.
Super: VABYSMO® (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with Neovascular (wet) Age-related Macular Degeneration (AMD).
Male Narrator: I was worried when I started to lose my sight, but my doctor recommended VABYSMO.
Super: VABYSMO
Male Narrator: VABYSMO is different. It’s the only
Super: Actor portrayal
Male Narrator: treatment thought to block two causes of wet AMD.
Super: VABYSMO is thought to block the VEGF and Ang-2 proteins. The benefit of blocking Ang-2 has yet to be established.
Male Narrator: So I’m back doing what I love knowing that
Super: Talk to your doctor or retina specialist to see if VABYSMO is right for you.
Male Narrator: VABYSMO improves vision.
Super: Clinical studies showed people on VABYSMO gained vision on an eye chart (6 letters on average), similar to those on aflibercept 2 mg through year 1.
Male Narrator: And there’s a chance for up to four months between treatments.
Super: After 4 initial monthly eye injections, your doctor or retina specialist will choose a schedule of 1 to 4 months based on patient response during your first year of treatment. Dosing may vary.
Super:  Talk to your doctor or retina specialist to see if VABYSMO is right for you.
Safety VO: VABYSMO is an eye injection. Don't take it if you have an infection, active eye swelling or are allergic to it.
Super: VABYSMO is an eye injection. Don’t take it if you have an infection, active eye swelling or are allergic to it.
Safety VO: VABYSMO could cause an eye infection, retinal detachment, temporary increase in eye pressure.
Super: VABYSMO could cause:
an eye infection or retinal detachment
temporary increase in eye pressure
Safety VO: An uncommon risk of heart attack or stroke.
Super: VABYSMO could cause:
an uncommon risk of heart attack or stroke
severe swelling of blood vessels in the eye
Safety VO: Or severe swelling of blood vessels in the eye. Report changes to vision or eye pain to your doctor or retina specialist right away.
Super: Report changes to vision or eye pain to your doctor or retina specialist right away.
Male Narrator: Now, I’m bringing it all into focus. Open up your world with VABYSMO.
Female VO: Trust the #1 prescribed FDA-approved treatment for wet AMD. Ask your retina specialist about VABYSMO.
SUPER: #1 PRESCRIBED FDA-APPROVED TREATMENT FOR WET AMD*
*Verana Health® patient share analysis (Apr-Jun 2025); products approved under separate applications considered individually (data on file).
Visit VABYSMO.com or call 1-8333-EYE-GENE for patient assistance programs, cost, and full Prescribing Information.

[H3] Adventure Awaits | Open Up Your World
When her vision started to blur due to wet AMD, she was scared to lose the world around her. Her retina specialist recommended VABYSMO. Now she’s back on the road with her granddaughter.

Now Playing 2 of 2
Open Transcript

Female Narrator: How did I get here? A grandma with vision loss from wet AMD. Riding across the desert.
Super: Wet AMD (Age-related Macular Degeneration)
Female Narrator: It started when VABYSMO opened up my world.
Super: VABYSMO® (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with Neovascular (wet) Age-related Macular Degeneration (AMD).
Female Narrator: I was worried I was losing sight of the world around me, but my doctor recommended VABYSMO.
Super: VABYSMO
Super: Actor portrayal
Female Narrator: VABYSMO is different. It’s the only treatment thought to block two causes of wet AMD.
Super: VABYSMO is thought to block the VEGF and Ang-2 proteins. The benefit of blocking Ang-2 has yet to be established.
Female Narrator: I was so excited when my granddaughter asked me to ride across the desert with her. Knowing that VABYSMO improves vision.
Super: Clinical studies showed people on VABYSMO gained vision on an eye chart (6 letters on average), similar to those on aflibercept 2 mg through year 1.
Female Narrator: And delivers a chance for up to four months between treatments.
Super: After 4 initial monthly eye injections, your doctor or retina specialist will choose a schedule of 1 to 4 months based on patient response during your first year of treatment. Dosing may vary.
Super:  Talk to your doctor or retina specialist to see if VABYSMO is right for you.
Safety VO: VABYSMO is an eye injection. Don't take it if you have an infection, active eye swelling, or are allergic to it.
Super: VABYSMO is an eye injection. Donʼt take it if you have an infection, active eye swelling or are allergic to it.
Safety VO: VABYSMO could cause eye infection, retinal detachment, temporary increase in eye pressure.
Super: VABYSMO could cause:
an eye infection or retinal detachment
temporary increase in eye pressure
Safety VO: An uncommon risk of heart attack or stroke, or severe swelling of blood vessels in the eye.
Super: VABYSMO could cause:
an uncommon risk of heart attack or stroke
severe swelling of blood vessels in the eye
Safety VO: Report changes to vision or eye pain to your doctor or retina specialist right away.
Super: Report changes to vision or eye pain to your doctor or retina specialist right away.
Female Narrator: Now I’ve got my sights set on the road ahead. Open up your world with VABYSMO.
Male VO: The number one prescribed treatment FDA-approved treatment for wet AMD. Ask your retina specialist about VABYSMO.
Super: #1 PRESCRIBED FDA-APPROVED TREATMENT FOR WET AMD*
*Verana Health® patient share analysis (Apr-Jun 2025); products approved under separate applications considered individually (data on file).
Visit VABYSMO.com or call 1-833-EYE-GENE for patient assistance programs, cost, and full Prescribing Information.

[H2] What is VABYSMO?
Take a tour through the eye and discover how VABYSMO works

Discover more

[H2] Treatment with VABYSMO
Explore clinical trial results and what to expect from treatment

See the difference

[H2] Financial support
Find out how you could save on your VABYSMO, even if you have no health insurance

Explore our options

[IMG: Image of Debra and David]

[IMG: Icon - Quote mark]

[H4] "My vision progressively got better, and I could see better.Ӧ
[H3]
David
[H5] VABYSMO patient

Watch his full story

Patient experiences may vary. Patients compensated by Genentech.
¶Clinical studies showed people on VABYSMO gained vision on an eye chart (6 letters on average), similar to those on aflibercept 2 mg through year 1.

NEXT: What is wet AMD?

Wet age-related macular degeneration (AMD) is a chronic eye condition that causes vision loss by damaging blood vessels in the eye. If left untreated, wet AMD can significantly impact visual function.
VABYSMO (faricimab-svoa) is approved to treat wet AMD. It’s thought to block 2 causes of vision loss (VEGF and Ang-2),‡ proteins that drive abnormal blood vessel swelling, leakage, and growth. The benefit of blocking Ang-2 has yet to be established. It also improves vision quickly.† On average, people gained 5 letters at 1 month after their first treatment and gained and maintained 6 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg.
VABYSMO is given by injection into the eye. Initial dosing will be every 4 weeks, then dosing is determined by your doctor based on how you respond. You may be able to go up to 4 months between treatments.§
The possible serious side effects of VABYSMO were inflammation and detached retina (separation of the retina from the back of the eye); a temporary increase in eye pressure; although not common, there is a risk of a stroke or heart attack; severe inflammation of vessels in the retina. These are not all the possible side effects of VABYSMO.

[H2]
IMPORTANT SAFETY INFORMATION

Back to Top

What is VABYSMO?
VABYSMO (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with neovascular (wet) age‑related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).
Do not receive VABYSMO if you:
Have an infection in or around your eye.
Have active swelling around your eye that may include pain and redness.
Are allergic to VABYSMO or any of the ingredients in VABYSMO.

What is the most important information I should know about VABYSMO?
Injections like the one for VABYSMO can cause an eye infection (endophthalmitis), separation of layers of the retina (retinal detachment), or inflammation in the eye that can lead to vision loss. Call your healthcare provider right away if your eye becomes red, sensitive to light, or you have a change or loss of vision.
VABYSMO may cause a temporary increase in pressure in the eye (intraocular pressure), which occurs within 60 minutes after receiving the eye injection.
Although not common, VABYSMO patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes (thromboembolic events). In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with VABYSMO reported such an event. In clinical studies for DME from baseline to week 100, 64 out of 1,262 patients treated with VABYSMO reported such an event. In clinical studies for RVO during 6 months, 7 out of 641 patients treated with VABYSMO reported such an event.
Severe inflammation of vessels in the retina has happened for patients treated with VABYSMO. Call your healthcare provider immediately if you experience a change in vision.
Before receiving VABYSMO, tell your healthcare provider about all of your medical conditions, including if you:
Are pregnant or plan to become pregnant. Based on how VABYSMO interacts with your body, there may be a potential risk to your unborn baby. You should use birth control before your first injection, during your treatment with VABYSMO, and for 3 months after your last dose of VABYSMO.
Are breastfeeding or plan to breastfeed. It is not known if VABYSMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive VABYSMO.
Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about all the medicines you take.
What should I avoid while receiving VABYSMO?
Your vision may be impaired after receiving an eye injection or after an eye exam. Do not drive or use machinery until your vision has recovered sufficiently.
What are the most common side effects with VABYSMO?
The most common side effects with VABYSMO were cataract and blood on the white of the eye (conjunctival hemorrhage).
These are not all the possible side effects of VABYSMO.
Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.
Please see the VABYSMO full Prescribing Information for additional Important Safety Information.
12930 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
0Review mentions (all pages)
6External proof links (all pages)
PageReviewsProof links
/ (home) 0 2
/important-safety-information.html 0 2
/es/index.html 0 0
/wamd.html 0 2
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema 
[
    {
        "@context": "http://schema.org",
        "@type": "Organization",
        "name": "Genentech",
        "url": "https://www.gene.com/",
        "logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
        "description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
        "contactPoint": {
            "@type": "ContactPoint",
            "telephone": "+1-877-436-3683",
            "contactType": "customer service"
        },
        "address": {
            "@type": "PostalAddress",
            "streetAddress": "1 DNA Way",
            "addressLocality": "South San Francisco",
            "addressRegion": "California",
            "postalCode": "94080",
            "addressCountry": "US"
        }
    },
    {
        "@context": "https://schema.org",
        "@type": "VideoObject",
        "name": "VABYSMO Phonetic Video",
        "description": "This video quickly explains how to say 'VABYSMO"",
        "thumbnailUrl": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/4b92eb25-b48c-4119-83a1-86b5237130da/86c3eb09-3ee5-40a7-8633-55a91e282a18/1280x720/match/image.jpg",
        "uploadDate": "2022-06-15T21:51:03.435Z",
        "duration": "PT15.381S"
    }
]
/important-safety-information.html 
[
    {
        "@context": "http://schema.org",
        "@type": "Organization",
        "name": "Genentech",
        "url": "https://www.gene.com/",
        "logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
        "description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
        "contactPoint": {
            "@type": "ContactPoint",
            "telephone": "+1-877-436-3683",
            "contactType": "customer service"
        },
        "address": {
            "@type": "PostalAddress",
            "streetAddress": "1 DNA Way",
            "addressLocality": "South San Francisco",
            "addressRegion": "California",
            "postalCode": "94080",
            "addressCountry": "US"
        }
    },
    {
        "@context": "https://schema.org",
        "@type": "VideoObject",
        "name": "VABYSMO Phonetic Video",
        "description": "This video quickly explains how to say 'VABYSMO"",
        "thumbnailUrl": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/4b92eb25-b48c-4119-83a1-86b5237130da/86c3eb09-3ee5-40a7-8633-55a91e282a18/1280x720/match/image.jpg",
        "uploadDate": "2022-06-15T21:51:03.435Z",
        "duration": "PT15.381S"
    }
]
/es/index.html 
[
    {
        "@context": "http://schema.org",
        "@type": "Organization",
        "name": "Genentech",
        "url": "https://www.gene.com/",
        "logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
        "description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
        "contactPoint": {
            "@type": "ContactPoint",
            "telephone": "+1-877-436-3683",
            "contactType": "customer service"
        },
        "address": {
            "@type": "PostalAddress",
            "streetAddress": "1 DNA Way",
            "addressLocality": "South San Francisco",
            "addressRegion": "California",
            "postalCode": "94080",
            "addressCountry": "US"
        }
    },
    {
        "@context": "https://schema.org",
        "@type": "VideoObject",
        "name": "VABYSMO Phonetic Video",
        "description": "This video quickly explains how to say 'VABYSMO"",
        "thumbnailUrl": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/4b92eb25-b48c-4119-83a1-86b5237130da/86c3eb09-3ee5-40a7-8633-55a91e282a18/1280x720/match/image.jpg",
        "uploadDate": "2022-06-15T21:51:03.435Z",
        "duration": "PT15.381S"
    }
]
/wamd.html 
[
    {
        "@context": "http://schema.org",
        "@type": "Organization",
        "name": "Genentech",
        "url": "https://www.gene.com/",
        "logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
        "description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
        "contactPoint": {
            "@type": "ContactPoint",
            "telephone": "+1-877-436-3683",
            "contactType": "customer service"
        },
        "address": {
            "@type": "PostalAddress",
            "streetAddress": "1 DNA Way",
            "addressLocality": "South San Francisco",
            "addressRegion": "California",
            "postalCode": "94080",
            "addressCountry": "US"
        }
    },
    {
        "@context": "https://schema.org",
        "@type": "VideoObject",
        "name": "Capturing All The Action | Open Up Your World",
        "description": "When he started to lose his vision due to wet AMD, he was worried about missing out on all the action. Then he heard about VABYSMO and now he can continue his passion for sports photography, capturing each moment at every turn.",
        "thumbnailUrl": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/00fa5e6d-ec90-4689-91ab-8cd3c7dc3beb/a0b9d81e-24a3-4a6e-bc78-06ead56f7fd9/1280x720/match/image.jpg",
        "uploadDate": "2026-03-13T13:25:25.234Z",
        "duration": "PT1M0.139S"
    },
    {
        "@context": "https://schema.org",
        "@type": "VideoObject",
        "name": "Adventure Awaits | Open Up Your World",
        "description": "When her vision started to blur due to wet AMD, she was scared to lose the world around her. Her retina specialist recommended VABYSMO. Now she’s back on the road with her granddaughter.",
        "thumbnailUrl": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/119275a7-943f-420d-ae0c-654656cf9e86/7ffa3349-c898-495c-ae67-c08cc88f5cca/1280x720/match/image.jpg",
        "uploadDate": "2026-02-09T20:22:12.733Z",
        "duration": "PT1M0.117S"
    },
    {
        "@context": "https://schema.org",
        "@type": "VideoObject",
        "name": "VABYSMO Phonetic Video",
        "description": "This video quickly explains how to say 'VABYSMO"",
        "thumbnailUrl": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/6125588073001/4b92eb25-b48c-4119-83a1-86b5237130da/86c3eb09-3ee5-40a7-8633-55a91e282a18/1280x720/match/image.jpg",
        "uploadDate": "2022-06-15T21:51:03.435Z",
        "duration": "PT15.381S"
    }
]

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence 0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof 0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint 0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority 0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score 0 / 100
💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS

Based on 784 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: VABYSMO (Genentech) (vabysmo.com)

https://vabysmo.com 📍 Industry: Medical Devices, Pharma & Biotech
18 BS / 100

This is a high-substance, low-BS pharmaceutical asset that prioritizes regulatory compliance and clinical data over marketing air. While it employs standard patient-centric cliches, it anchors every emotional hook in rigid, quantitative clinical proof.

Info Density Power-words vs. Substance ratio.
6
20% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
2
10% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
4
20% BS
Commodity Fingerprint Detection of industry clichés/templates.
5
33% BS
Identity & Authority Expert verifiability & Schema depth.
1
7% BS

Replace the generic ‘Open Up Your World’ H3 headings with specific outcome headers like ‘Sustained Vision Gains over 12 Months.’ Provide direct links to peer-reviewed publications in the Lancet or NEJM rather than relying on ‘data on file’ for market share statistics. Add ClinicalTrials.gov identifiers (e.g., NCT numbers) directly next to clinical outcome summaries for maximum transparency. Ensure that the ‘data on file’ from June 2025 is updated as it approaches the ‘stale’ 12-month threshold relative to the current 2026 system date.

The content perfectly aligns with the Pharma & Biotech industry, characterized by heavy regulatory disclosure, clinical trial data citations, and a focus on therapeutic mechanisms of action. The use of ‘faricimab-svoa’ and detailed safety protocols confirms the pharmaceutical nature of the entity.

“The low BS score is driven by high specificity in performance claims and an absence of semantic drift. Minor points were deducted for the use of generic industry value prop cliches ('Open Up Your World') and the use of 'data on file' citations which are less transparent than public database links.”

Verified Analysis Date: May 26, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution

This training module utilizes a snapshot of public data from VABYSMO (Genentech), captured on May 26, 2026, to demonstrate how machine logic evaluates different types of business narratives.

Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.

Notice to VABYSMO (Genentech): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.

Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.

To all users: You are encouraged to visit the live site at https://vabysmo.com to view the most current version of its content and learn from the source what this company is about and what it offers.

Brand AI Reputation